Tosk

Executive Summary

Tosk, Inc. is a biopharmaceutical company dedicated to improving cancer treatment outcomes by developing small molecule drugs that selectively block the adverse side effects of existing cancer therapies. Founded in 2008 and based in Mountain View, CA, the company also employs a proprietary discovery platform to target previously 'undruggable' cancer genes, starting with mutant KRAS. By mitigating toxicity, Tosk aims to enhance patient quality of life and enable more effective use of established oncology regimens, addressing a critical unmet need in cancer care. Despite being in operation for over a decade, Tosk remains private with limited public disclosure of funding or pipeline details, suggesting a lean, research-focused approach. The company's dual strategy—reducing side effects and tackling hard-to-drug targets like KRAS—positions it uniquely in the oncology space. Upcoming catalysts could include clinical trial initiations, preclinical data releases, or strategic partnerships, which would provide key validation of its platform. However, the lack of recent transparency warrants cautious optimism.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for mutant KRAS inhibitor30% success
• Q3 2026Publication of preclinical data for side effect reduction program50% success
• Q2 2027Strategic partnership or licensing deal for discovery platform25% success